Bill

Bill > HR878


US HR878

US HR878
Right to Try Act of 2017


summary

Introduced
02/06/2017
In Committee
03/02/2017
Crossed Over
Passed
Dead
12/31/2018

Introduced Session

115th Congress

Bill Summary

Right to Try Act of 2017 This bill requires the federal government to allow unrestricted manufacturing, distribution, prescribing, and dispensing of experimental drugs, biological products, and medical devices that are: (1) intended to treat a patient who has been diagnosed with a terminal illness, and (2) authorized by state law. The federal government must allow unrestricted possession and use of such treatments by patients certified by a physician as having exhausted all other treatment options. A manufacturer, distributor, prescriber, dispenser, possessor, or user of such a treatment has no liability regarding the treatment. The outcome of manufacture, distribution, prescribing, dispensing, possession, or use of such a treatment may not be used by a federal agency to adversely impact review or approval of the treatment. The treatment must: (1) have successfully completed a phase 1 (initial, small scale) clinical trial; (2) remain under investigation in a clinical trial approved by the Food and Drug Administration; and (3) not be approved, licensed, or cleared for sale under the Federal Food, Drug, or Cosmetic Act or the Public Health Service Act.

AI Summary

This bill, the Right to Try Act of 2017, requires the federal government to allow unrestricted manufacturing, distribution, prescribing, and dispensing of experimental drugs, biological products, and medical devices that have successfully completed a phase 1 clinical trial, remain under investigation by the FDA, and are not yet approved for commercial sale. The federal government must allow unrestricted possession and use of such treatments by patients certified by a physician as having exhausted all other treatment options and being diagnosed with a terminal illness. The bill also provides liability protection for the manufacturer, distributor, prescriber, dispenser, possessor, or user of such treatments, and prohibits the use of the outcomes of these treatments to adversely impact the review or approval of the treatments by federal agencies.

Committee Categories

Business and Industry, Health and Social Services, Justice

Sponsors (90)

Andy Biggs (R)* Ralph Abraham (R),  Rick Allen (R),  Jodey Arrington (R),  Don Bacon (R),  Jim Banks (R),  Lou Barletta (R),  Andy Barr (R),  Diane Black (R),  Rod Blum (R),  Mike Bost (R),  Dave Brat (R),  Jim Bridenstine (R),  Mo Brooks (R),  Vern Buchanan (R),  Ken Buck (R),  Ted Budd (R),  Bradley Byrne (R),  André Carson (D),  Steve Chabot (R),  Mike Coffman (R),  James Comer (R),  Barbara Comstock (R),  Lou Correa (D),  Kevin Cramer (R),  John Culberson (R),  Scott DesJarlais (R),  Jeff Duncan (R),  John Faso (R),  Brian Fitzpatrick (R),  Trent Franks (R),  Matt Gaetz (R),  Mike Gallagher (R),  Tom Garrett (R),  Bob Gibbs (R),  Louie Gohmert (R),  Paul Gosar (R),  Tom Graves (R),  Morgan Griffith (R),  Glenn Grothman (R),  Karen Handel (R),  Andy Harris (R),  Vicky Hartzler (R),  Jeb Hensarling (R),  Jaime Herrera Beutler (R),  Jody Hice (R),  Clay Higgins (R),  French Hill (R),  Darrell Issa (R),  Mike Johnson (R),  Jim Jordan (R),  Peter King (R),  Raúl Labrador (R),  Doug LaMalfa (R),  Doug Lamborn (R),  Leonard Lance (R),  Jason Lewis (R),  Blaine Luetkemeyer (R),  Tom Marino (R),  Roger Marshall (R),  Martha McSally (R),  Mark Meadows (R),  Luke Messer (R),  Alex Mooney (R),  Ralph Norman (R),  Pete Olson (R),  Stevan Pearce (R),  Scott Perry (R),  Robert Pittenger (R),  Ted Poe (R),  Jared Polis (D),  Bill Posey (R),  John Ratcliffe (R),  David Roe (R),  Dana Rohrabacher (R),  Todd Rokita (R),  Keith Rothfus (R),  Mark Sanford (R),  David Schweikert (R),  F. James Sensenbrenner (R),  Kyrsten Sinema (I),  Lloyd Smucker (R),  Chris Stewart (R),  Claudia Tenney (R),  G.T. Thompson (R),  Scott Tipton (R),  Tim Walberg (R),  Randy Weber (R),  Kevin Yoder (R),  Ted Yoho (R), 

Last Action

Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations. (on 03/02/2017)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...